Clinical markers of long-term disability in RRMS patients treated with interferon beta

被引：0
|
作者：
Rio, J. [1 ]
Otero-Romero, S. [1 ,2 ]
Tintore, M. [1 ]
Comabella, M. [1 ]
Nos, C. [1 ]
Negrotto, L. [1 ]
Galan, I. [1 ]
Vidal-Jordana, A. [1 ]
Castillo, J. [1 ]
Palavra, F. [1 ]
Simon, E. [1 ]
Arrambide, G. [1 ]
Sastre-Garriga, J. [1 ]
Montalban, X. [1 ]
机构：
[1] Vall Hebron Univ Hosp, Multiple Sclerosis Ctr Catalonia, Dept Neuroimmunol, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Prevent Med & Epidemiol Dept, Barcelona, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P285
引用
收藏
页码：194 / 194
页数：1
相关论文
共 50 条
  • [21] The value of MRS, a novel MRI technique, as a predictor of disability: analysis at 20-years of RRMS patients treated long-term with glatiramer acetate
    Khan, O.
    Bao, F.
    Ford, C.
    Kolodny, S.
    Vainstein, A.
    Sidi, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 284 - 284
  • [22] Disease activity as assessed by the MAGNIMS score predicts long-term clinical disease activity (CDA)-free status and disability progression in patients treated with subcutaneous interferon beta-1a
    Sormani, M. P.
    Freedman, M. S.
    Aldridge, J.
    Marhardt, K.
    de Stefano, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 318 - 318
  • [23] 16-year long-term follow-up of interferon beta-1b treatment in RRMS
    Ebers, G
    Rice, G
    Wolf, C
    Traboulsee, A
    Langdon, D
    Kaskel, P
    Salazar-Grueso, E
    NEUROLOGY, 2005, 64 (06) : A385 - A385
  • [24] Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort
    Bigaut, Kevin
    Fabacher, Thibaut
    Kremer, Laurent
    Ongagna, Jean-Claude
    Kwiatkowski, Arnaud
    Sellal, Franois
    Ferriby, Didier
    Courtois, Sylvie
    Vermersch, Patrick
    Collongues, Nicolas
    Zephir, Helene
    De Seze, Jerome
    Outteryck, Olivier
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 729 - 741
  • [25] Long-term follow-up of multiple sclerosis patients treated with interferon beta-1a (Avonex®)
    Vermersch, R
    Denève, M
    Waucquier, N
    de Seze, J
    MULTIPLE SCLEROSIS, 2005, 11 : S75 - S75
  • [26] A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin
    Li, Xiaoting
    Zhou, Yi
    Jiang, Jianning
    Long, Shiyu
    Dong, Guozhen
    Su, Man
    Li, Jijiao
    Wei, Yanchun
    Su, Minghua
    DISCOVERY MEDICINE, 2023, 35 (178) : 868 - 876
  • [27] Long-term real-life retrospective analysis on interferon β1-a use in RRMS patients in Finland
    Murtonen, A.
    Vuorio, J.
    Jarvinen, E.
    Wiksten, A.
    Sumelahti, M-L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 887 - 887
  • [28] Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
    Sormani, Maria Pia
    Truffinet, Philippe
    Thangavelu, Karthinathan
    Rufi, Pascal
    Simonson, Catherine
    De Stefano, Nicola
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (05):
  • [29] Long-term β interferon in MS: safe, but what effect on disability?
    Scolding, Neil J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (08): : 825 - 826
  • [30] Long-term outcome improvement in patients with chronic hepatitis D treated with interferon α
    Ratziu, Vlad
    Poynard, Thierry
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 76 - 77
12345